同德化工(002360.SZ):擬向山西落基山增資2.5億元
格隆匯 2 月 5日丨同德化工(002360.SZ)公佈,公司為促進公司多元發展,培育新的利潤增長點,公司擬與山西落基山光伏能源科技有限公司(“標的公司”或“山西落基山”)進行投資合作。同德化工擬設新能源材料合夥企業,合夥企業以現金方式出資約2.5億元對標的公司進行增資,此次增資完成後,合夥企業將成為山西落基山光伏能源科技有限公司的第一大股東。
此次投資光伏行業生產多晶硅的山西落基山光伏能源科技有限公司,是以劉立新博士帶領的技術團隊,實現了以硅泥為原料的全工藝的連續生產出合格成品硅錠,且拉單晶成功,此產品與目前主流“改良西門子化學法”產品質量一致,已完全具備大規模產業化應用推廣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.